On August 7, 2024 Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities oering dierentiated products to patients, today reported nancial results for the second quarter ended June 30, 2024 (Press release, Assertio Holdings, AUG 7, 2024, View Source [SID1234647065]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"In my rst two months at Assertio, I have been excited to work closely with the team, meet our growing list of oncology clinic customers and focus on how best to maximize our results going forward. The second quarter’s performance illustrates how we continue to diligently execute the three pillars of Assertio’s business plan: driving the nancial performance of Assertio’s key assets, including our lead asset Rolvedon, generating cash ow and identifying new assets to create further value for our stockholders," said Brendan O’Grady, who was appointed Chief Executive Ocer on May 29, 2024.

"Rolvedon has been well received by physicians and continues to increase its share of the oncology G-CSF market,
generating its sixth consecutive quarter of demand growth since launch. As a potential opportunity for further
dierentiation, we have also completed enrollment of Rolvedon’s same-day dosing trial and expect to present the
initial data at a medical conference later this year. Combined with the rest of our platform and pipeline of
prospective business development opportunities, I am excited about the potential for Assertio."